Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Arranon
Nelarabine is a prodrug of ara-G, a purine nucleoside analog. It is used to treat T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) that has not responded to or has relapsed after treatment with other chemotherapy drugs. Nelarabine is cytotoxic to T-cells by interfering with DNA synthesis and repair, leading to apoptosis.
Treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).
Nelarabine can cause severe neurologic toxicity, including seizures, encephalopathy, and peripheral neuropathy. Patients should be closely monitored for neurologic symptoms.
Outcome:
Increased risk of nelarabine toxicity
Mechanism:
Inhibition of nelarabine metabolism
Outcome:
May increase risk of hepatotoxicity
Mechanism:
Additive effects on liver function
Outcome:
May decrease nelarabine absorption
Mechanism:
Changes in gastric pH
Most likely new formulation: Liposomal nelarabine for improved delivery and reduced toxicity (Year: 2026, 60% confidence)
Based on current usage trends and clinical trial outcomes, there is a low likelihood of regulatory changes affecting nelarabine's approval status within the next 2 years.
Antineoplastic, Antimetabolite, Purine Nucleoside Analog
Purine Nucleoside Analog